Figure 6.

Enumeration of human leukocytes in tumor-bearing humanized mice treated with nivolumab. Mononuclear cells were prepared from the indicated tissues of huNOG or huNOG-FcγR^−/− mice. The cells were analyzed by flow cytometry. The absolute cell number of each cell lineage was calculated by multiplying the total cell number with the frequency. Data from a representative experiment were shown for each tumor cell line. The numbers of mice are as follows. For HSC4 and RKO, huNOG mice (n = 5 or 5 for saline- or nivolumab-treated mice, respectively) and huNOG-FcγR^−/− mice (n = 4 or 5 for saline- or nivolumab-treated mice, respectively). For NCI-H1975, huNOG mice (n = 5 or 5 for saline- or nivolumab-treated mice, respectively) and huNOG-FcγR^−/− mice (n = 5 or 4 for saline- or nivolumab-treated mice, respectively). For HCC827, huNOG mice (n = 5 or 5 for saline- or nivolumab-treated mice, respectively) and huNOG-FcγR^−/− mice (n = 4 or 4 for saline- or nivolumab-treated mice, respectively). Note that a fewer number of mice were analyzed for TIL because of the limited tumor size and all tumor tissues were used for IHC analysis (n = 1 or 2 for HSC4- or NCI-H1975-bearing Nivolumab-treated huNOG-FcγR^−/− mice, respectively, and n = 3, 2, or 4 for NCI-H1975-, HCC827-, or RKO-bearing saline-treated huNOG mice, respectively). Statistical significance was tested using two-way ANOVA with Sidak’s multiple comparison test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).